JP Morgan Maintains Neutral on Conmed, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 71.5%

Neg 71.5% Neu 0% Pos 0%

JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Neutral and lowers the price target from $43 to $40.